Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed To Outsource API Production To India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Nycomed will transfer production of active pharmaceutical ingredients from facilities in Austria and Germany to India over the next four years as it expands a joint venture with Zydus Cadila, the Swiss company announced March 11

You may also be interested in...



For Burgeoning Emerging Markets, All Business is Local

With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago

For Burgeoning Emerging Markets, All Business is Local

With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago

Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors

Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel